Formulation of roselle extract water-in-oil nanoemulsion for controlled pulmonary delivery.

The anthocyanin (ACN)-rich roselle extract has the potential to inhibit lung cancer. However, the compounds demonstrate low bioavailability and stability in biological applications. The present study proposed a stable formulation of a water-in-oil (w/o) roselle extract nanoemulsion by combining low...

Full description

Saved in:
Bibliographic Details
Main Authors: Baba Shekh, Adil Omer, Abdul Wahab, Roswanira, Yahya, Nur Azzanizawaty
Format: Article
Published: Taylor and Francis Ltd. 2023
Subjects:
Online Access:http://eprints.utm.my/106466/
https://doi.org/10.1080/01932691.2022.2046044
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anthocyanin (ACN)-rich roselle extract has the potential to inhibit lung cancer. However, the compounds demonstrate low bioavailability and stability in biological applications. The present study proposed a stable formulation of a water-in-oil (w/o) roselle extract nanoemulsion by combining low (hot temperature inversion) and high-energy approaches (ultrasonication and ultra-homogenization) for pulmonary delivery. The stable w/o formulation comprised of roselle extract (0.04 w/w%), sodium chloride solution (3.0 w/w%), medium-chain triglyceride (81.9 w/w%), surfactant (Tween 80 and Span 80) (15.0 w/w%), hydrophilic-lipophilic balance (HLB) of 6.7 [Tween 80/Span 80 (22.5:77.5)] to yield the stable nanoemulsion.The best nanoemulsion showed an average 298 nm particle size, polydispersity index of 0.6, and zeta potential of −49.0 mV. The emulsions were stable in the centrifuge- and freeze-thaw cycle tests,-alongside the 60-days storage tests at 4 °C, 25 °C, and 35 °C. The in-vitro release of the roselle extract at pH 6.5 buffer was 44.7% and 40.7% at pH 7.4 (p > 0.05), with the release patterns following the non-Fickian diffusion. Hence, the present study successfully developed a stable w/o roselle extract nanoemulsion with a relatively moderate release rate of the ACNs, supporting its suitability as a nanocarrier for pulmonary delivery.